Tiratricol

From Self-sufficiency
Jump to: navigation, search
Tiratricol
File:Tiratricol.svg
Systematic (IUPAC) name
[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid
Pharmacokinetic data
Protein binding Presumed high
Metabolism Hepatic glucuronidation
Excretion Biliary
Identifiers
CAS Number 51-24-1
ATC code H03AA04 (WHO) D11AX08
PubChem CID 5803
Synonyms 3,3',5-triiodothyroacetic acid
TRIAC
Chemical data
Formula C14H9I3O4
Molar mass 621.932 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Tiratricol (also known as TRIAC or triiodothyroacetic acid) is a thyroid hormone analogue.

Uses

It is indicated in the management of thyroid hormone resistance syndrome[1] and is used, in combination with levothyroxine, to suppress thyroid-stimulating hormone production in patients with thyroid cancer.

It has been investigated for use in reducing goiter.[2]

It has also shown some effectiveness in reducing the atrophy caused when using corticosteroids.[3]

Tiratricol has also been widely marketed, under various trade names, as a weight loss aid. In 1999 and 2000, the United States Food and Drug Administration and Health Canada both issued warnings to the public regarding the use of dietary supplements containing tiratricol.[4][5]

Legal status

Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale.[6]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Other dermatological preparations (D11)
Medicated shampoos
Cetrimide - Cadmium compounds - Selenium compounds - Povidone-iodine - Sulfur compounds - Xenysalate
Other dermatologicals
Other
Thyroid therapy (H03)
Thyroid hormones
Antithyroid preparations
Block conversion of T4 to T3
Other


45px This hormonal preparation article is a stub. You can help ssf by expanding it.
40px This dermatologic drug article is a stub. You can help ssf by expanding it.
tr:Tiratrikol
  1. ↑ Carvalho GA, Ramos HE (2004). "[Thyroid hormone resistance syndrome]". Arq Bras Endocrinol Metabol (in Portuguese). 48 (1): 83–92. doi:/S0004-27302004000100010 Check |doi= value (help). PMID 15611821.  Free full textPDF (95.3 KiB)
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  4. ↑ "FDA Warns Against Consuming Dietary Supplements Containing Tiratricol" (Press release). U.S. Food and Drug Administration. November 21, 2000. http://www.fda.gov/bbs/topics/ANSWERS/ANS01057.html. Retrieved 2007-08-08. 
  5. ↑ "Health Canada issues warning on products containing Tiratricol (TRIAC)" (Press release). Health Canada. December 2, 1999. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/1999/1999_143_e.html. Retrieved 2007-08-08. 
  6. ↑ "Anvisa suspende Tiratricol" (in Portuguese). Brazilian Society of Endocrinology and Metabolism. Retrieved 2007-08-08. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Tiratricol&oldid=28539"